← The Wire·Consumer·

Lilly combo cuts diabetic patients’ weight by up to 23% in 48 weeks

Eli Lilly’s experimental eloralintide-Mounjaro combination produced average weight loss of up to 23% in people with diabetes over 48 weeks. The result gives Lilly another late-stage obesity-treatment asset as it competes with Novo Nordisk in a rapidly expanding market.

STOCK PHOTO · MAURÍCIO MASCARO

The story

Participants receiving the highest dose lost an average of 54 pounds over 48 weeks, according to Bloomberg. Their A1C declined 2.9 percentage points from a baseline of 8.1%, and as many as three-quarters reached normal blood-sugar levels.

The combination pairs eloralintide, Lilly’s experimental obesity drug, with Mounjaro, its tirzepatide treatment for diabetes and obesity. The reported result adds to Lilly’s existing position in metabolic medicines and changes the competitive comparison with Novo Nordisk from single-drug performance toward combination regimens.

For Lilly, the commercial mechanism would run through demand for Mounjaro alongside a potential new eloralintide franchise. The reported weight-loss and glucose-control figures are from people with diabetes, so the read-through depends on how the combination performs across broader patient groups and in later-stage testing.

The report describes experimental results rather than an approved combination. Questions remain around durability, safety, dosing, regulatory requirements and whether the reported efficacy translates into a commercially viable treatment. The next evidence should come from additional clinical data and Lilly’s regulatory or development updates on eloralintide.

Our read · Thu, Oct 1

LLY’s eloralintide-Mounjaro combination delivered up to 23% average weight loss and a 2.9-point A1C decline in diabetics.

Why. The result expands Lilly’s potential obesity franchise beyond Mounjaro, with the reported 23% weight loss and 2.9-point A1C reduction providing a concrete efficacy hook. Lilly already generated $65.2B of FY2025 revenue and a 31.7% net margin, so a successful combination could build on an established commercial platform, but the treatment remains experimental and the next clinical and regulatory steps are not dated here.

Both cases

The case it holdsUp to 23% average weight loss, 54 pounds lost at the highest dose and a 2.9-point A1C reduction could support a differentiated combination franchise alongside Lilly’s established Mounjaro business.
The case it breaksThe evidence is limited to a reported 48-week experimental result in people with diabetes, leaving durability, safety, regulatory status and commercial uptake unresolved.

What could change this view: The read fails if later trials show weaker efficacy, unacceptable safety or dosing constraints, or regulators do not support the combination’s use.

Eli Lilly stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

More on LLY

US judge lets Eli Lilly keep weight-loss ads in Novo Nordisk caseNovo Nordisk shares slide 7.7% as turnaround plans face analyst doubt

Latest on the Wire

BlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by ZeroHedge as Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →